TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04394533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prilocaine (Hyperbaric 2%)
Description: 2 ml hyperbaric prilocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine (Hyperbaric 0.5%)
Description: 2 ml hyperbaric bupivacaine
Study: NCT06773910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986489
Description: BMS-986489 (fixed dose combination of atigotatug + nivolumab) will be administered as an intravenous infusion to be given once every 4 weeks for up to 2 years.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Durvalumab will be administered as a fixed dose intravenous infusion to be given once every 4 weeks for up to 2 years.
Study: NCT06770179

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: recruitment maneuver
Description: in the group 2, in addition to the fixed PEEP of 5 cm H₂O, a recruitment maneuver is planned at the end of the surgery. This will involve administering 6 breaths with VC × 2, I/E ratio of 1:1, and a plateau pressure of less than 35 cm H₂O, before extubation.
Study: NCT04683965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2 d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: TAS-102, capsule, 35mg/m2, bid,p.o, d1\~5,d8\~12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 5 mg/kg d1,d14
Study: NCT05776862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursolic Acid
Description: Subjects will take an oral 400mg (8 capsules - 4 in the morning/200mg and 4 at night/200mg) supplement of UA every day for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursolic Acid
Description: Subjects will take an oral 400mg (8 capsules - 4 in the morning/200mg and 4 at night/200mg) supplement of UA every day for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength Training
Description: Subjects will perform 3 sets of 10 repetitions of concentric and eccentric upper body exercises (bicep curls and tricep extensions) each session. Each session will last approximately 10-15 minutes of weightlifting with a 2-minute rest period between sets. The arm selected for exercise will be randomized.
Study: NCT06417021

Intervention type: OTHER
Group type: OTHER
Intervention: Frontal Ultrasound Machine
Description: Ultrasound machine will be placed in a frontal position

Intervention type: OTHER
Group type: OTHER
Intervention: Lateral Ultrasound Machine
Description: Ultrasound machine will be placed in a lateral position
Study: NCT06343675

Intervention type: OTHER
Intervention: There is no intervention
Description: There is no intervention
Study: NCT06089642

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Virtual reality based on distraction and Virtual Reality based on focussed attention
Study: NCT05458388

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kimura-Takemoto classification
Description: All patients were given two risk scores, the order of which was randomly determined.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EGGIM
Description: All patients were given two risk scores, the order of which was randomly determined.
Study: NCT04670640

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration
Description: Participants will attend two intervention sessions per week for a total of 8 sessions. Participants will sit in a chair in a sound-proof booth monitored by a researcher in front of a computer screen (which delivers instructions) and will be fitted with psychophysiology leads and a device strapped around the chest. There will be no explicit tasks or direction given in this intervention. Participants will experience smooth slowly varying breath-like vibration on their sternum. They will receive their assigned intervention for approximately 18 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration
Description: Participants will attend two intervention sessions per week for a total of 8 sessions. Participants will sit in a chair in a sound-proof booth monitored by a researcher in front of a computer screen (which delivers instructions) and will be fitted with psychophysiology leads and a device strapped around the chest. There will be no explicit tasks or direction given in this intervention. Participants will experience smooth slowly varying breath-like vibration on their sternum. They will receive their assigned intervention for approximately 18 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breath Focus
Description: Participants will attend two intervention sessions per week for a total of 8 sessions. Participants will sit in a chair in a sound-proof booth monitored by a researcher in front of a computer screen (which delivers instructions) and will be fitted with psychophysiology leads and a device strapped around the chest. The participant will be asked to focus on their breathing during this intervention. They will receive their assigned intervention for approximately 18 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breath Focus
Description: Participants will attend two intervention sessions per week for a total of 8 sessions. Participants will sit in a chair in a sound-proof booth monitored by a researcher in front of a computer screen (which delivers instructions) and will be fitted with psychophysiology leads and a device strapped around the chest. The participant will be asked to focus on their breathing during this intervention. They will receive their assigned intervention for approximately 18 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Distractions
Description: Participants will attend two intervention sessions per week for a total of 8 sessions. Participants will sit in a chair in a sound-proof booth monitored by a researcher in front of a computer screen (which delivers instructions) and will be fitted with psychophysiology leads and a device strapped around the chest. Participants will engage in a period of no-screen time; during this time there will be no outside visual or auditory distractions. There will be no explicit tasks or direction given in this intervention. They will receive their assigned intervention for approximately 18 minutes.
Study: NCT05607875

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Grow to Recovery Train-the-Trainer program
Description: Mental health professionals will receive an online training, a trainer manual, a recovery manual (for people with mental illness), and Pathways to Recovery: A Strengths Recovery Self-help Workbook. The online training includes the concept of recovery, the implementation of recovery-oriented services, and the introduction of the Grow to recovery group. After the training, these professionals will conduct a 5-month Grow to recovery group in their own organization.~People with mental illness will attend the Grow to recovery group delivered by mental health professionals who has received the online training.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Mental health professionals will not receive any training. People with mental illness will receive a spiritual book and read by themselves.
Study: NCT04697628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tisotumab vedotin
Description: 2.0 mg/kg every 3 weeks (Q3W)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topotecan
Description: 1 or 1.25 mg/m2 intravenous (IV) on Days 1 to 5, every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinorelbine
Description: 30 mg/m2 IV on Days 1 and 8, every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: 1000 mg/m2 IV on Days 1 and 8, every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan
Description: 100 or 125 mg/m2 IV weekly for 28 days, every 42 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed
Description: 500 mg/m2 IV on Day 1, every 21 days
Study: NCT05670587

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A wearable cough monitoring device, the Strados Labs RESPᵀᴹ sensor, with an accompanying mobile application (App) for data collection
Description: A wearable cough monitoring device, the Strados Labs Remote Electronic Stethoscope Platform (RESP)ᵀᴹ sensor, with an accompanying mobile application (App) for data collection.
Study: NCT04417894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dupilumab
Description: Solution for subcutaneous (SC) injection administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solution for SC injection administration
Study: NCT05347160

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biodentine
Description: using of biodentine , calcium hydroxide and platelet rich fibrin as pulpotomy agents

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biodentine
Description: using of biodentine , calcium hydroxide and platelet rich fibrin as pulpotomy agents

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biodentine
Description: using of biodentine , calcium hydroxide and platelet rich fibrin as pulpotomy agents
Study: NCT06017804

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle energy technique
Description: Participants were required to adopt a supine position. MET's post-isometric relaxation method was chosen. The therapist gently flexed the patient's hip until the limitation bar-rier was detected. At this stage, isometric contractions against resistance were applied. After that, the patients were told to resist the movement with only 25% of their strength. Before the leg was released, the contraction was maintained for 7-10 seconds. On exhale, the knee joint was straightened (extended) towards its new barrier, and a stretch was applied and maintained through that barrier for 30 seconds. This procedure was carried out six times.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-myofascial release technique
Description: A foam roller was rolled from the ischial tuberosity to the back of the knee on the side being tested while the participant remained seated in a long sitting position. Individuals were instructed to keep all of their body weight on the leg being evaluated. They spent 30-40 seconds rolling one hamstring at a time in each set (10 times back and forth).
Study: NCT05667896

Intervention type: DRUG
Intervention: glucocorticoid + tacrolimus
Description: Prednisone 0.4-0.5mg/kg/d; Tacrolimus 0.05-0.10mg/kg/d, oral administration in two times, with an interval of 12h. The drug valley concentration is 5-10ng/ml, which will be gradually reduced to a low dose after it becomes effective.

Intervention type: DRUG
Intervention: glucocorticoid + tacrolimus
Description: Prednisone 0.4-0.5mg/kg/d; Tacrolimus 0.05-0.10mg/kg/d, oral administration in two times, with an interval of 12h. The drug valley concentration is 5-10ng/ml, which will be gradually reduced to a low dose after it becomes effective.
Study: NCT05448911

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative navigation combined with Catheter screw technique
Description: It uses minimally invasive small incisions, physiological access to the pelvis, and hollow screws for Pelvic and Acetabular fractures

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open reduction and internal fixation with steel plate
Description: Open reduction and plate internal fixation is the most commonly used method to treat pelvic fracture, which can achieve anatomical reduction and rigid fixation. However, this method requires extensive dissection of the surrounding soft-tissue fracture and is invasive
Study: NCT06144905

Intervention type: OTHER
Intervention: standard care treatment program
Description: The standard care treatment consists of a program of psychotherapy and nutritional rehabilitation to achieve normalization of food-intake and weight gain.
Study: NCT06017596

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEEK framework
Description: All-on-4 implants with PEEK framework of fixed detachable prosthesis
Study: NCT05185271

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyad-focused strategy training
Description: Rehabilitation therapists will be hired to deliver the intervention to the stroke survivors-caregiver dyads on a one-to-two base. The therapist will ask the dyad to identify their shared goals and provide them the global strategy Goal-Plan-Do-Check (also called guided discovery strategy), which involves (1) setting a goal to address the barriers, (2) developing a plan to address the goal, (3) doing the plan, and (4) checking if the plan worked or required revising. This procedure will be repeated iteratively until the dyad's goal is met, and the next goal can be moved on to.
Study: NCT04011020

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Stem Cell Educator therapy
Description: Patients with T1D will be evaluated by the study principal investigator or co-investigators. Informed consent will be obtained at the initial screening visit. The initial screening visit will occur within 30 days of initiation of SCE therapy. The second screening visit will occur within 7 days of therapy. Subjects who meet all criteria will be scheduled for treatment. All enrolled subjects will receive treatment with the SCE system consisting of a single session of mononuclear cells (MNC) collection by apheresis where 10 L of blood will be processed on day -1. The MNC product will then be exposed over to the SCE and on day 0 the product will be infused intravenously back to the patient.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Stem Cell Educator therapy
Description: Patients with T1D will be evaluated by the study principal investigator or co-investigators. Informed consent will be obtained at the initial screening visit. The initial screening visit will occur within 30 days of initiation of SCE therapy. The second screening visit will occur within 7 days of therapy. Subjects who meet all criteria will be scheduled for treatment. All enrolled subjects will receive treatment with the SCE system consisting of a single session of mononuclear cells (MNC) collection by apheresis where 10 L of blood will be processed on day -1. The MNC product will then be exposed over to the SCE and on day 0 the product will be infused intravenously back to the patient.
Study: NCT04607200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGEN2034
Description: Anti-PD-1 Monoclonal Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGEN2034
Description: Anti-PD-1 Monoclonal Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGEN1884
Description: Anti-CTLA-4 Monoclonal Antibody
Study: NCT05903846

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oketani massage
Description: The part between the breast and the base of the lower pectoral muscle is called the oketani. It is a manual massage technique developed to encourage breastfeeding in breastfeeding problems such as insufficient milk production and mastitis. It is a massage that stimulates the breast, relaxes it and is painless.
Study: NCT06463600

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magseed
Description: Tumour localizer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Metallic clip and guide wire
Description: Tumour localizers
Study: NCT06339528

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vojta's Reflex Locomotion
Description: Reflex locomotion according to Vojta's therapy is a neurorehabilitative concept originally used for diagnostics and treatment of infants who were at risk of non-physiological psychomotor development, especially spastic cerebral palsy. This concept utilizes stimulation of specific zones described by Vojta to evoke global motor and non-motor response.~Trigger zones are specific body zones that are stimulated with pressure during reflex locomotion stimulation. They are pressure stimulated in order to induce reflex response. Variations of stimulation of different trigger zones (spatial summation) causes multiplication of afferent impulses. Sufficiently long stimulation of trigger zones (temporal summation) induces isometric contraction in muscle groups described by Vojta.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham stimulation
Description: Control group received sham stimulation by physicians at zones outside of the pressure zones, specifically 4-5 cm above the patella and on the lateral malleolus.
Study: NCT05170243

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 9MW1911 Injection
Description: Single dose intravenously on day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 9MW1911 Injection Placebo
Description: Single dose of matching placebo intravenously on day 1
Study: NCT04797065

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 6-minute then 9-minute withdrawal
Description: Patients in 6-minute then 9-minute withdrawal group will first be carefully observed in 2 minutes then in 3 minutes during each colonic segment.~In actual performance, withdrawal of the right colon, transverse colon and the left colon can be operated in segmental tandem colonoscopy. Taking the right colon as an example, after the endoscope reaches the cecum, it can be withdrawn to the splenic curvature in 2 minutes, then reentered the cecum and withdrawn to the splenic curvature in 3 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 9-minute then 6-minute withdrawal
Description: Patients in 9-minute then 6-minute withdrawal group will first be carefully observed in 3 minutes then in 2 minutes during each colonic segment.~In actual performance, withdrawal of the right colon, transverse colon and the left colon can be operated in segmental tandem colonoscopy. Taking the right colon as an example, after the endoscope reaches the cecum, it can be withdrawn to the splenic curvature in 3 minutes, then reentered the cecum and withdrawn to the splenic curvature in 2 minutes.
Study: NCT04978207

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A Faithful Response to COVID-19
Description: See previous description

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A Faithful Response to COVID-19
Description: See previous description
Study: NCT06266143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y101D
Description: Intravenous infusion of Y101D at day1, combined with Gemcitabine and Nab-Paclitaxel IV infusion at day1, 8, a 21-day cycle. After 6 cycles, Y101D and Gemcitabine infusion is applied as the maintenance treatment.
Study: NCT05450146

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Partner in Balance
Description: The Partner in Balance intervention (Boots, 2018) consists of 1) a face-to-face intake session with a care professional (casemanagers, dementia nurses or district nurses) to familiarize participants with the program, set goals, and select preferred module themes; 2) tailored online thematic modules, including psychoeducation, behavioral modeling, reflective assignments, set goals, and online messaging feedback with the care professional over 8 weeks; and 3) a face-to-face evaluation session with the care professional evaluating previously set goals.
Study: NCT05954442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus is a kind of mTOR inhibitors which has been approved to use in several kinds of cancers, especially in metastatic breast cancer .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigator's Choice of Chemotherapy
Description: Investigator's choice of chemotherapy means the chemotherapy chosen by investigators/doctors to treat metastatic triple negative breast cancer, including nab-paclitaxel, capecitabine, eribulin, carboplatin, vinorelbine, or utidelone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigator's Choice of Chemotherapy
Description: Investigator's choice of chemotherapy means the chemotherapy chosen by investigators/doctors to treat metastatic triple negative breast cancer, including nab-paclitaxel, capecitabine, eribulin, carboplatin, vinorelbine, or utidelone.
Study: NCT05551832

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Arm I (Placebo),
Description: Placebo after Pylurus preserving Pancreaticoduodenctomy (PPPD) for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm II (ESMESOL)
Description: SMESOL 40 mg dose administrea daily at bedtime for 6 months after PPPD ,
Study: NCT05157815

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soluble Fibre
Description: 10g soluble corn fibre to be consumed twice per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calorie Matched Control
Description: 2g maltodextrin consumed twice per day
Study: NCT06241040

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercises with core Muscle strengthening
Description: Participants assigned to this group will undergo a combination of aerobic exercise and core muscle strengthening interventions. The aerobic exercise component will be similar to the first group, while additional exercises targeting the core muscles (abdomen, back, and pelvis) will be included.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise without Core Muscle Strengthening
Description: Aerobic Exercise without Core Muscle Strengthening
Study: NCT05183750

Intervention type: PROCEDURE
Group type: OTHER
Intervention: High tibial osteotomy
Description: Opening wedge high tibial osteotomy will be done according to the measurement preoperatively and fixation will be by plate and screws.
Study: NCT04770051

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous inferior cervical sympathetic block
Description: The procedure will be performed while the patient was awake and under fluoroscopic guidance. A total of 3 ml of 1% lidocaine will be infiltrated to anesthetize the skin and subcutaneous tissues down to the left common carotid artery. A 22 gauge × 3.5 inch BD™ Quincke spinal needle will be introduced at the level of the body of the sixth cervical vertebra, medial to the left common carotid artery. The needle will be advanced until it reached the junction between the body and transverse process of the sixth cervical vertebra. Contrast injection will be used to demonstrate the position of the needle anterior to the paravertebral muscles, with spread along the axis of the interfascial compartment (Figure 1). A total of 20 ml of 0.25% bupivacaine (Marcaine, Hospira, Lake Forest, IL) will be injected over 10 min through the needle. The effectiveness of sympathetic blockade will be confirmed by postprocedure development of ptosis and miosis in the left eye.
Study: NCT05442307

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: asthma education
Description: A 15 minutes (preferable) one-on-one educational visit about asthma treatment. The main points being: Every person with asthma should be treated with inhaled corticosteroids (ICS). Most patients with asthma should be treated with Bufomix Easyhaler either as needed and/or regularly. Patients should not use short-acting bega2-agonist (SABA) unless they use a medium-ICS-dosis.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Other education
Description: A 15 minutes (preferable) one-on-one educational visit about another topic (NOT asthma).